- Home
- MVST vs AMRN Comparison
MVST vs AMRN Comparison
Compare MVST & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.00
HOLD
Current Price
$13.75
Company Overview
Basic Information| Metric | MVST | AMRN |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.0M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | MVST | AMRN |
|---|---|---|
| Price | $3.00 | $13.75 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 4.5M | 87.3K |
| Earning Date | 11-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,504,000.00 | $226,733,000.00 |
| Revenue This Year | $24.19 | N/A |
| Revenue Next Year | $17.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $1.09 | $7.08 |
| 52 Week High | $7.12 | $20.90 |
Technical Indicators
Market Signals| Indicator | MVST | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 32.49 |
| Support Level | $3.28 | $13.41 |
| Resistance Level | $3.16 | $14.30 |
| Average True Range (ATR) | 0.19 | 0.72 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 19.45 | 8.95 |
Price Performance
Historical Comparison MVST
AMRN
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.